Related Research Articles
A Klatskin tumor is a cholangiocarcinoma occurring at the confluence of the right and left hepatic bile ducts. The disease was named after Gerald Klatskin, who in 1965 described 15 cases and found some characteristics for this type of cholangiocarcinoma
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers. They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor therapy.
Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. Serum levels can also be elevated in heavy smokers.
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention." More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular.
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung, and the rest of the body.
Tumor M2-PK is a synonym for the dimeric form of the pyruvate kinase isoenzyme type M2 (PKM2), a key enzyme within tumor metabolism. Tumor M2-PK can be elevated in many tumor types, rather than being an organ-specific tumor marker such as PSA. Increased stool (fecal) levels are being investigated as a method of screening for colorectal tumors, and EDTA plasma levels are undergoing testing for possible application in the follow-up of various cancers.
Carbohydrate antigen 19-9 (CA19-9), also known as sialyl-LewisA, is a tetrasaccharide which is usually attached to O-glycans on the surface of cells. It is known to play a role in cell-to-cell recognition processes. It is also a tumor marker used primarily in the management of pancreatic cancer.
Mesothelin, also known as MSLN, is a protein that in humans is encoded by the MSLN gene.
Urachal cancer is a very rare type of cancer arising from the urachus or its remnants. The disease might arise from metaplastic glandular epithelium or embryonic epithelial remnants originating from the cloaca region.
Medullary thyroid cancer is a form of thyroid carcinoma which originates from the parafollicular cells, which produce the hormone calcitonin. Medullary tumors are the third most common of all thyroid cancers and together make up about 3% of all thyroid cancer cases. MTC was first characterized in 1959.
Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary, breast, colon, lung, and pancreatic cancers. It is a mucin-like molecule with a molar mass of over 1000 kDa.
Galectin-4 is a protein that in humans is encoded by the LGALS4 gene.
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e, is a member of the carcinoembryonic antigen (CEA) gene family.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.
A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer, with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor relapse.
Thymidine kinase is an enzyme, a phosphotransferase : 2'-deoxythymidine kinase, ATP-thymidine 5'-phosphotransferase, EC 2.7.1.21 that catalyzes the reaction:
Nita Ahuja is a surgeon and the Chair of the Department of Surgery at Yale School of Medicine and Surgeon-in-Chief of Surgery at Yale New Haven Hospital. She is the first woman ever to serve as Chair of Surgery in Yale in its >200 year history. Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at Johns Hopkins Hospital, Baltimore, USA. Ahuja researches in the field of epigenetics and is a passionate advocate of clinician scientist. She also served as the director of Sarcoma and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature.
Albumin transport function analysis by EPR spectroscopy is an in vitro blood test that detects changes to the transport and molecular conformation of serum albumin using the method of EPR spectroscopy. The test is used for diagnosis of cancer, sepsis and toxemia.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
References
- ↑ Louhimo J, Alfthan H, Stenman UH, Haglund C (2004). "Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer". Oncology. 66 (2): 126–31. doi:10.1159/000077438. PMID 15138364. S2CID 25798287.
- ↑ Haglund C, Lundin J, Kuusela P, Roberts PJ (September 1994). "CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA". Br. J. Cancer . 70 (3): 487–92. doi:10.1038/bjc.1994.332. PMC 2033366 . PMID 8080735.
- ↑ Röthlin MA, Joller H, Largiadèr F (February 1993). "CA 242 is a new tumor marker for pancreatic cancer". Cancer. 71 (3): 701–7. doi:10.1002/1097-0142(19930201)71:3<701::AID-CNCR2820710308>3.0.CO;2-C. PMID 8431849.
- ↑ Ni, X.G.; Bai, X.F.; Mao, Y.L.; Shao, Y.F.; Wu, J.X.; Shan, Y.; Wang, C.F.; Wang, J.; Tian, Y.T. (March 2005). "The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer". European Journal of Surgical Oncology (EJSO). 31 (2): 164–169. doi:10.1016/j.ejso.2004.09.007. ISSN 0748-7983. PMID 15698733.
- ↑ Gu, Yu-Lei; Lan, Chao; Pei, Hui; Yang, Shuang-Ning; Liu, Yan-Fen; Xiao, Li-Li (2015-10-06). "Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy". Asian Pacific Journal of Cancer Prevention . 16 (15): 6569–6573. doi: 10.7314/apjcp.2015.16.15.6569 . ISSN 1513-7368. PMID 26434876.
- ↑ Dou, Huaiqian; Sun, Guirong; Zhang, Lijuan (2019-01-01), Zhang, Lijuan (ed.), "Chapter Twelve - CA242 as a biomarker for pancreatic cancer and other diseases", Progress in Molecular Biology and Translational Science, Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A, 162, Academic Press: 229–239, doi:10.1016/bs.pmbts.2018.12.007, PMID 30905452, S2CID 85498143 , retrieved 2021-12-03
- ↑ Hasmik, Vahradyan (2011). "The Role of CA-19-9, CA 242 and CEA Tumor Markers in Digestive Tract Cancer Diagnostics". Clinical Biochemistry . 44 (13): S209. doi:10.1016/j.clinbiochem.2011.08.520.
 | This biochemistry article is a stub. You can help Wikipedia by expanding it. |